Thorac Cardiovasc Surg 2015; 63(08): 663-669
DOI: 10.1055/s-0035-1549356
Original Cardiovascular
Georg Thieme Verlag KG Stuttgart · New York

One-Year Clinical Outcome after Left Ventricular Assist Device Malfunction

U. Cenk Oezpeker
1   Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany
,
Armin Zittermann
1   Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany
,
Guelsuem Erkilet
1   Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany
,
Uwe Schulz
1   Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany
,
Stephan Ensminger
1   Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany
,
Jan F. Gummert
1   Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany
,
Michiel Morshuis
1   Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany
› Author Affiliations
Further Information

Publication History

26 November 2014

17 February 2015

Publication Date:
04 May 2015 (online)

Abstract

Background Left ventricular assist device (LVAD) implants bear the risk of driveline/device infections and technical failures.

Methods We assessed clinical outcome in LVAD patients with device-related complications. Group 1 (n = 12) received device exchange (DEx) as destination therapy (DT), group 2 (n = 15) received DEx as a bridge to transplant (BTT), group 3 (n = 34) was allocated to receive high-urgency (HU) heart transplantation (HTx), and group 4 (n = 27) had device-related complications that could only be solved by HTx. Primary endpoint was 1-year overall survival.

Results Age and Simplified Acute Physiology Score II differed significantly between groups and were highest in group 1, lowest in group 3. One-year survival in groups 1 to 4 was 66.7, 60.0, 82.4, and 70.4% (p = 0.30). Covariate-adjusted odds ratio of 1-year survival (reference: group 1) was for group 2 = 1.52 (95% confidence interval [CI]: 0.42–5.57), for group 3 = 1.13 (95% CI: 0.28–4.56), and for group 4 = 1.89 (95% CI: 0.51–7.04; p for trend 0.70). Clinical complications (need of mechanical ventilator support, extracorporeal circulatory membrane oxygenation (ECMO) implants, kidney/liver dialysis) were comparable between groups.

Conclusion Data indicate similar 1-year clinical outcomes in LVAD patients with device-related complications receiving DEx or HTx.

 
  • References

  • 1 UNOS annual report 2013: http://srtr.transplant.hrsa.gov//annual_reports/2012/pdf/05_heart_13 . Accessed December 15, 2014
  • 2 Eurotransplant annual report 2013: https://www.eurotransplant.org/cms/mediaobject.php?file=AR20135 . Accessed December 15, 2014
  • 3 Stehlik J, Hosenpud JD, Edwards LB, Hertz MI, Mehra MR ; International Society for Heart and Lung Transplantation. ISHLT International Registry for Heart and Lung Transplantation—into the fourth decade, from strength to strength. J Heart Lung Transplant 2013; 32 (10) 941-950
  • 4 Lietz K, Long JW, Kfoury AG , et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007; 116 (5) 497-505
  • 5 Slaughter MS, Meyer AL, Birks EJ. Destination therapy with left ventricular assist devices: patient selection and outcomes. Curr Opin Cardiol 2011; 26 (3) 232-236
  • 6 Schibilsky D, Benk C, Haller C , et al. Double tunnel technique for the LVAD driveline: improved management regarding driveline infections. J Artif Organs 2012; 15 (1) 44-48
  • 7 Abicht T, Gordon R, Meehan K, Stosor V, McCarthy P, McGee Jr E. Complex HeartMate II infection treated with pump exchange to HeartWare HVAD. ASAIO J 2013; 59 (2) 188-192
  • 8 Fleissner F, Avsar M, Malehsa D, Strueber M, Haverich A, Schmitto JD. Reduction of driveline infections through doubled driveline tunneling of left ventricular assist devices. Artif Organs 2013; 37 (1) 102-107
  • 9 Jafar M, Gregoric ID, Radovancevic R, Cohn WE, McGuire N, Frazier OH. Urgent exchange of a HeartMate II left ventricular assist device after percutaneous lead fracture. ASAIO J 2009; 55 (5) 523-524
  • 10 Potapov EV, Kaufmann F, Stepanenko A , et al. Pump exchange for cable damage in patients supported with HeartMate II left ventricular assist device. ASAIO J 2012; 58 (6) 578-582
  • 11 Birks EJ, Tansley PD, Yacoub MH , et al. Incidence and clinical management of life-threatening left ventricular assist device failure. J Heart Lung Transplant 2004; 23 (8) 964-969
  • 12 Adzic A, Patel SR, Maybaum S. Impact of adverse events on ventricular assist device outcomes. Curr Heart Fail Rep 2013; 10 (1) 89-100
  • 13 Kirklin JK, Naftel DC, Pagani FD , et al. Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant 2014; 33 (6) 555-564
  • 14 Dowling RD, Park SJ, Pagani FD , et al. HeartMate VE LVAS design enhancements and its impact on device reliability. Eur J Cardiothorac Surg 2004; 25 (6) 958-963
  • 15 Hunt SA. Taking heart—cardiac transplantation past, present, and future. N Engl J Med 2006; 355 (3) 231-235
  • 16 Lund LH, Edwards LB, Kucheryavaya AY , et al; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report–2013; focus theme: age. J Heart Lung Transplant 2013; 32 (10) 951-964
  • 17 Cosío Carmena MD, Gómez Bueno M, Almenar L , et al. Primary graft failure after heart transplantation: characteristics in a contemporary cohort and performance of the RADIAL risk score. J Heart Lung Transplant 2013; 32 (12) 1187-1195
  • 18 Tenderich G, Zittermann A, Schulz U , et al. Heart transplantation at the Heart Center North Rhine-Westfalia. Clin Transpl 2008; 151-161
  • 19 Hetzer R, Delmo Walter EM. Trends and outcomes in heart transplantation: the Berlin experience. HSR Proc Intensive Care Cardiovasc Anesth 2013; 5: 76-80
  • 20 Kirklin JK, Naftel DC, Pagani FD , et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation?. J Thorac Cardiovasc Surg 2012; 144 (3) 584-603 , discussion 597–598